Allscripts Healthcare Solutions
The 10-second takeaway
For the quarter ended March 31 (Q1), Allscripts Healthcare Solutions missed estimates on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share contracted significantly.
Margins dropped across the board.
Allscripts Healthcare Solutions notched revenue of $364.7 million. The 18 analysts polled by S&P Capital IQ looked for sales of $387.6 million on the same basis. GAAP reported sales were 8.8% higher than the prior-year quarter's $335.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.12. The 19 earnings estimates compiled by S&P Capital IQ predicted $0.24 per share. GAAP EPS of $0.03 for Q1 were 50% lower than the prior-year quarter's $0.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.7%, 500 basis points worse than the prior-year quarter. Operating margin was 3.6%, 640 basis points worse than the prior-year quarter. Net margin was 1.6%, 220 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $403.2 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $1.64 billion. The average EPS estimate is $1.09.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 461 members out of 491 rating the stock outperform, and 30 members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 105 give Allscripts Healthcare Solutions a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allscripts Healthcare Solutions is outperform, with an average price target of $23.58.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Allscripts Healthcare Solutions the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Allscripts Healthcare Solutions to My Watchlist.